精(jing)華(hua)制(zhi)(zhi)(zhi)藥集團股(gu)份有限(xian)(xian)公司(si)是由(you)南(nan)(nan)通(tong)(tong)產控集團控股(gu)、國(guo)資(zi)(zi)監管的地方國(guo)有控股(gu)企(qi)業,由(you)原(yuan)南(nan)(nan)通(tong)(tong)中誠(cheng)制(zhi)(zhi)(zhi)藥有限(xian)(xian)公司(si)(南(nan)(nan)通(tong)(tong)中藥廠)變更、重組南(nan)(nan)通(tong)(tong)制(zhi)(zhi)(zhi)藥總廠(南(nan)(nan)通(tong)(tong)制(zhi)(zhi)(zhi)藥廠、南(nan)(nan)通(tong)(tong)制(zhi)(zhi)(zhi)藥二廠)優質資(zi)(zi)源,并吸(xi)收(shou)民營資(zi)(zi)本南(nan)(nan)通(tong)(tong)綜藝投資(zi)(zi)有限(xian)(xian)公司(si)以及自然(ran)人投資(zi)(zi)設立。2010年(nian)2月(yue)在(zai)深交(jiao)所(suo)中小(xiao)板掛牌(pai)上市,股(gu)票簡稱:精(jing)華(hua)制(zhi)(zhi)(zhi)藥,證券代號:002349。
公司(si)(si)已有60多(duo)年的(de)制(zhi)(zhi)藥(yao)(yao)(yao)歷(li)史,是一家綜合性的(de)現(xian)代化GMP制(zhi)(zhi)藥(yao)(yao)(yao)有限公司(si)(si)。目前(qian)擁有7個子公司(si)(si),是一家集中(zhong)(zhong)藥(yao)(yao)(yao)制(zhi)(zhi)劑、中(zhong)(zhong)藥(yao)(yao)(yao)飲片(pian)、西(xi)藥(yao)(yao)(yao)制(zhi)(zhi)劑、醫藥(yao)(yao)(yao)中(zhong)(zhong)間(jian)體、化學(xue)原料(liao)藥(yao)(yao)(yao)、生(sheng)物(wu)制(zhi)(zhi)藥(yao)(yao)(yao)、保(bao)健品(pin)(pin)等(deng)(deng)生(sheng)產(chan)、銷(xiao)售和研(yan)發的(de)綜合型(xing)制(zhi)(zhi)藥(yao)(yao)(yao)企業集團(tuan)。公司(si)(si)有中(zhong)(zhong)西(xi)藥(yao)(yao)(yao)品(pin)(pin)種(zhong)(zhong)(zhong)200余種(zhong)(zhong)(zhong),中(zhong)(zhong)藥(yao)(yao)(yao)產(chan)品(pin)(pin)主要(yao)有享譽海內外的(de)經典(dian)名藥(yao)(yao)(yao)“五朵金花”王氏保(bao)赤丸(wan)、季德勝蛇藥(yao)(yao)(yao)片(pian)、正柴胡飲顆粒、大柴胡顆粒、金蕎麥膠囊,以(yi)及(ji)(ji)固(gu)本咳喘片(pian)、暈可平糖漿、精血補片(pian)等(deng)(deng),這些中(zhong)(zhong)藥(yao)(yao)(yao)品(pin)(pin)種(zhong)(zhong)(zhong)都有著廣泛的(de)歷(li)史背景(jing)及(ji)(ji)深厚的(de)文化底蘊,其中(zhong)(zhong)季德勝蛇藥(yao)(yao)(yao)片(pian)、王氏保(bao)赤丸(wan)制(zhi)(zhi)作技(ji)藝均被(bei)列入國(guo)(guo)家非物(wu)質文化遺產(chan)。原料(liao)藥(yao)(yao)(yao)產(chan)品(pin)(pin)主要(yao)有苯巴比妥、撲米酮(tong)、氟尿嘧啶(ding)(ding)、保(bao)泰松(song)、氟胞嘧啶(ding)(ding)、吡羅昔康、替諾昔康、丙硫氧嘧啶(ding)(ding)、非那西(xi)丁、雙嘧達莫以(yi)及(ji)(ji)其它醫藥(yao)(yao)(yao)中(zhong)(zhong)間(jian)體等(deng)(deng)。其中(zhong)(zhong)已有10個品(pin)(pin)種(zhong)(zhong)(zhong)通過(guo)國(guo)(guo)家GMP認(ren)證,5個品(pin)(pin)種(zhong)(zhong)(zhong)通過(guo)歐(ou)盟CEP認(ren)證,2個品(pin)(pin)種(zhong)(zhong)(zhong)通過(guo)澳(ao)大利(li)亞GMP認(ren)證,3個品(pin)(pin)種(zhong)(zhong)(zhong)通過(guo)墨西(xi)哥官方(fang)認(ren)證,4個品(pin)(pin)種(zhong)(zhong)(zhong)獲得美(mei)國(guo)(guo)DMF注(zhu)冊(ce)文件(jian) ,1個品(pin)(pin)種(zhong)(zhong)(zhong)獲得美(mei)國(guo)(guo)VMF注(zhu)冊(ce)文件(jian),并(bing)已通過(guo)美(mei)國(guo)(guo)FDA現(xian)場(chang)核查(cha)。
精華制藥(yao)(yao)(yao)(yao)將會以(yi)“成為(wei)以(yi)傳(chuan)(chuan)世(shi)中(zhong)藥(yao)(yao)(yao)(yao)為(wei)核(he)心(xin)特(te)色(se)的(de)全(quan)國現(xian)代(dai)醫藥(yao)(yao)(yao)(yao)企業(ye)”為(wei)戰略目標,深入貫(guan)徹(che)《關于促(cu)進中(zhong)醫藥(yao)(yao)(yao)(yao)傳(chuan)(chuan)承(cheng)創新發(fa)展(zhan)的(de)意見》精神(shen),聚焦“五朵金花”傳(chuan)(chuan)世(shi)中(zhong)藥(yao)(yao)(yao)(yao)主(zhu)業(ye)為(wei)主(zhu),特(te)色(se)化學原(yuan)料(liao)藥(yao)(yao)(yao)(yao)及化學制劑為(wei)輔(fu)的(de)“雙輪驅(qu)動”的(de)發(fa)展(zhan)戰略,依托品牌力和(he)渠道(dao)力,致力于成為(wei)以(yi)傳(chuan)(chuan)世(shi)中(zhong)藥(yao)(yao)(yao)(yao)為(wei)核(he)心(xin)特(te)色(se)的(de)全(quan)國現(xian)代(dai)醫藥(yao)(yao)(yao)(yao)企業(ye)。